NCT/Study#
NCT05651932 /
K-36-KTX-MMSET-001
A Phase 1 Study of an oral, first-in-class, selective, and potent MMSET catalytic inhibitor that suppresses H3K36me2 in patients with Relapsed and Refractory Multiple Myeloma
DISEASE GROUP:
Multiple Myeloma
current phase:
Phase I
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
